
Table of Contents

Post-Authorization – March 29, 2021: Terms and Conditions (Control#: 250727)]2
Post-Authorization – April 6, 2021: Terms and Conditions (Control#: 250727)	



Health Products and Food Branch

Direction générale des produits de santé et des aliments

Biologic and Radiopharmaceutical Drugs Directorate 100 Eglantine Driveway LCDC Building, Tunney's Pasture, A.L. 0601C Ottawa, Ontario K1A 0K9

March 29, 2021

Dossier ID: HC6-024-E241458

Control #: 250727

INTERIM ORDER AUTHORIZATION AMENDMENT–TERMS AND CONDITIONS

Health Canada is aware of the increasing number of reports of rare thrombotic events with thrombocytopenia that have been reported following immunization with the AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant]). Health Canada is also aware of a proposed mechanism of action, which provides support for biological plausibility of an association between the vaccine and these events. As a result, Health Canada is considering whether additional action is required related to the recommended uses of the vaccine to mitigate these risks. To determine whether additional risk mitigation measures are needed, Health Canada is requesting that AstraZeneca Canada Inc. provide additional information to support the ongoing use of the AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant]) as is currently indicated in Canada.

In accordance with section 10 of the *Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19*, the following Terms and Conditions are imposed on the authorization issued in respect of AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant]):

RISK MANAGEMENT PLAN:

- 1. AstraZeneca Canada Inc. will provide by April 5, 2021, an assessment of the benefits and the risks, stratified by sex and age, for the use of the COVID-19 vaccine in the current Canadian context, taking into consideration disease projections and the epidemiology of circulating variants, and post-market reports of rare thrombotic events, including those associated with thrombocytopenia.
- 2. AstraZeneca Canada Inc. will provide an analysis, by March 31, 2021, of the proposed or alternate mechanisms of development of thrombotic events with thrombocytopenia considering available case reports and data.
- 3. AstraZeneca Canada Inc. will propose additional pharmacovigilance activities, including in the Canadian context, for those individuals who receive(d) the vaccine, to be submitted by March 31, 2021.
- 4. AstraZeneca Canada Inc. will provide an assessment of the need for and propose any additional risk minimization measures that could be applied in the Canadian context, to be submitted by March 31, 2021.



The information above is to be reflected in the revised Risk Management Plan, requested on March 26, 2021, for submission by April 8, 2021. Health Canada wishes to remind AstraZeneca Canada Inc. of the requirement to notify Health Canada without delay of any international regulatory actions taken in relation to this or any other issue, as per Section C.01.050 of the Food and Drug Regulations.





Health Products and Food Branch

Direction générale des produits de santé et des aliments

Biologic and Radiopharmaceutical Drugs Directorate 100 Eglantine Driveway LCDC Building, Tunney's Pasture, A.L. 0601C Ottawa, Ontario K1A 0K9

April 6, 2021

Dossier ID: HC6-024-E241458

Control #: 250727

INTERIM ORDER AUTHORIZATION AMENDMENT–TERMS AND CONDITIONS

Further to the request received April 5, 2021 and the follow up correspondence, Health Canada is amending the Terms and Conditions issued March 29, 2021. This amendment provides an extension for AstraZeneca Canada Inc. to provide a complete response to Term #1 issued March 29, 2021 no later than April 7, 2021, taking into account the global updates to the AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant]).

In accordance with section 10 of the *Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19*, the following Terms and Conditions are imposed on the authorization issued in respect of AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant]):

RISK MANAGEMENT PLAN:

1. AstraZeneca Canada Inc. will provide by April 7, 2021, an assessment of the benefits and the risks, stratified by sex and age, for the use of the COVID-19 vaccine in the current Canadian context, taking into consideration disease projections and the epidemiology of circulating variants, and post-market reports of rare thrombotic events, including those associated with thrombocytopenia.

Health Canada wishes to remind AstraZeneca Canada Inc. of the requirement to notify Health Canada without delay of any international regulatory actions taken in relation to this or any other issue, as per Section C.01.050 of the Food and Drug Regulations.

